Octreotide acetate CR is under clinical development by ASCIL Biopharm and currently in Phase I for Neuroendocrine Tumors. According to GlobalData, Phase I drugs for Neuroendocrine Tumors have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Octreotide acetate CR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Octreotide acetate CR overview
Octreotide is under development for the treatment of neuroendocrine tumors (NET) and acromegaly. It is a controlled release formulation administered through subcutaneous and intramuscular route. The drug candidate acts by targeting somatostatin receptor (SSTR).
ASCIL Biopharm overview
ASCIL Biopharm (Ascil) operates as a developer of patented injectable and commercial controlled-release therapeutics. The company develops advanced drug delivery system formulations and medical devices for the administration of drugs for chronic diseases. Its pipeline includes formulations for quarterly administration of high-dose biologics; and immediate release ready-to-use drug delivery system of emergency drugs and peptides for chronic disease. Ascil conducts research and development programs to achieve product performance for safety issues related to intravitreal long-acting products and dermo-cosmetic targeted delivery technologies for skin health improvements. The company offers its solutions in the field of pharma, biotech, aesthetic and veterinary care. Ascil is headquartered in Viladecans, Spain.
For a complete picture of Octreotide acetate CR’s drug-specific PTSR and LoA scores, buy the report here.